Table 4.

Effect of germline miRNA SNP on breast cancer–specific mortality among invasive cases

		Model 1a		Model 2b
SNP	Genotype	HR (95% CI)	P1-valuec	HR (95% CI)	P2-valuec
Overall
miR-16-1/15a	GG	Referent
rs9535416d	AG+AA	1.05 (0.82 – 1.33)	0.70	1.12 (0.87 – 1.44)	0.40
miR-34b/34c	TC+TT	Referent
rs4938723e	CC	0.57 (0.37 – 0.89)	0.01	0.65 (0.42 – 1.02)	0.06
miR-206	AA	Referent
rs6920648e	AG+GG	0.77 (0.61 – 0.97)	0.02	0.79 (0.62 – 1.00)	0.05
African American
miR-16-1/15a	GG	Referent
rs9535416d	AG+AA	1.05 (0.78 – 1.42)	0.74	1.16 (0.85 – 1.58)	0.35
miR-34b/34c	TC+TT	Referent
rs4938723e	CC	0.49 (0.25 – 0.95)	0.03	0.63 (0.32 – 1.23)	0.18
miR-206	AA	Referent
rs6920648e	AG+GG	0.85 (0.63–1.14)	0.28	0.93 (0.68 – 1.25)	0.62
Caucasian
miR-16-1/15a	GG	Referent
rs9535416d	AG+AA	1.04 (0.70 – 1.56)	0.84	1.03 (0.67 – 1.59)	0.89
miR-34b/34c	TC+TT	Referent
rs4938723e	CC	0.66 (0.37 – 1.20)	0.17	0.65 (0.36 – 1.18)	0.16
miR-206	AA	Referent
rs6920648e	AG+GG	0.66 (0.47–0.94)	0.02	0.62 (0.43 – 0.90)	0.01
ER+ tumor status
miR-16-1/15a	GG	Referent
rs9535416d	AG+AA	0.86 (0.59 – 1.27)	0.45	0.90 (0.60 – 1.35)	0.61
miR-34b/34c	TC+TT	Referent
rs4938723e	CC	0.42 (0.20 – 0.90)	0.03	0.54 (0.25 – 1.17)	0.12
miR-206	AA	Referent
rs6920648e	AG+GG	0.74 (0.52 – 1.07)	0.11	0.77 (0.53 – 1.12)	0.18
ER− tumor status
miR-16-1/15a	GG	Referent
rs9535416d	AG+AA	1.28 (0.92 – 1.77)	0.14	1.25 (0.90 – 1.73)	0.19
miR-34b/34c	TC+TT	Referent
rs4938723e	CC	0.78 (0.45 – 1.36)	0.38	0.81 (0.47 – 1.40)	0.45
miR-206	AA	Referent
rs6920648e	AG+GG	0.81 (0.59 – 1.10)	0.18	0.80 (0.58 – 1.09)	0.16

^aModel 1; Hazard Ratio adjusted for age, self-reported race (as appropriate) and ancestry

^bModel 2; Hazard Ratio adjusted for age, self-reported race (as appropriate), stage (1,2,3+4), and ancestry

^cP-value is unadjusted for multiple comparisons

^dGenotype categories collapsed due to small cell size

^eGenotype categories collapsed due to nearly identical survival rates